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Introduction: Synovial fibroblasts invade cartilage and bone, leading to joint destruction in rheumatoid arthritis.
However, the mechanisms that regulate synovial fibroblast invasion are not well understood. Focal adhesion kinase
(FAK) has been implicated in cellular invasion in several cell types, and FAK inhibitors are in clinical trials for cancer
treatment. Little is known about the role of FAK in inflammatory arthritis, but, given its expression in synovial tissue,
its known role in invasion in other cells and the potential clinical availability of FAK inhibitors, it is important to
determine if FAK contributes to synovial fibroblast invasion and inflammatory arthritis.
Methods: After treatment with FAK inhibitors, invasiveness of human rheumatoid synovial fibroblasts was
determined with Matrigel invasion chambers. Migration and focal matrix degradation, two components of cellular
invasion, were assessed in FAK-inhibited rheumatoid synovial fibroblasts by transwell assay and microscopic examination
of fluorescent gelatin degradation, respectively. Using mice with tumor necrosis factor α (TNFα)–induced arthritis in which
fak could be inducibly deleted, invasion and migration by FAK-deficient murine arthritic synovial fibroblasts were
determined as described above and arthritis was clinically and pathologically scored in FAK-deficient mice.
Results: Inhibition of FAK in human rheumatoid synovial fibroblasts impaired cellular invasion and migration. Focal matrix
degradation occurred both centrally and at focal adhesions, the latter being a novel site for matrix degradation in synovial
fibroblasts, but degradation was unaltered with FAK inhibitors. Loss of FAK reduced invasion in murine arthritic synovial
fibroblasts, but not migration or TNFα-induced arthritis severity and joint erosions.
Conclusions: FAK inhibitors reduce synovial fibroblast invasion and migration, but synovial fibroblast migration
and TNFα-induced arthritis do not rely on FAK itself. Thus, inhibition of FAK alone is unlikely to be sufficient to treat
inflammatory arthritis, but current drugs that inhibit FAK may inhibit multiple factors, which could increase their
efficacy in rheumatoid arthritis.Introduction
Synovial fibroblasts are critical for the pathogenesis of
rheumatoid arthritis. These cells normally line the joint,
but in rheumatoid arthritis they increase in number as
part of the pannus, a tumorlike structure that causes sig-
nificant joint destruction [1]. Synovial fibroblasts secrete
inflammatory cytokines, degrade cartilage and bone [2,3]
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stated.models [4]. Despite the fact that their ability to invade
can be pathologic, little is known about what mediates
synovial fibroblast invasion.
Cellular invasion is a multistep process that involves
cell adhesion at the site of invasion, formation of inva-
sive structures, focal matrix degradation and migration
through the newly degraded area to continue the inva-
sion process. Different cell types generate different
structures to invade. Arthritic rat [5] and possibly hu-
man rheumatoid [6] synovial fibroblasts make invado-
podia, structures often used by cancer cells to invade
and metastasize [7]. Cancer cells recently have beentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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structures that function primarily as cellular anchors.
Focal adhesion kinase (FAK) is a nonreceptor protein
tyrosine kinase and scaffolding protein that mediates nu-
merous cellular functions, including adhesion, migration
and invasion [9]. FAK can be found in different parts of
the cell, but is often localized to focal adhesions in part
through interactions with paxillin [10]. Downstream of in-
tegrin binding, FAK becomes activated, which involves au-
tophosphorylation of tyrosine 397 and leads to a signaling
cascade ultimately resulting in cytoskeletal reorganization
and other activities [11,12]. FAK has been implicated in in-
vasion in normal cells such as macrophages [13], as well
as in tumor cells [9]. Further, FAK inhibitors are being
studied in clinical trials for cancer treatment [14]. One of
these agents, PF-562,271, reduces pancreatic and prostate
cancer metastases in mice [15,16], supporting a role for
FAK in cellular invasion and metastatic disease in vivo.
Given the importance of synovial fibroblast invasion
in rheumatoid arthritis, FAK may be important in
rheumatoid arthritis pathogenesis. Rheumatoid synovial
tissue has increased phosphorylated FAK and tumor ne-
crosis factor α (TNFα) can induce FAK phosphorylation
in rheumatoid synovial fibroblasts [17], which induces
matrix metalloproteases [9]. Further, rapamycin, which de-
creases the invasiveness of arthritic synovial fibroblasts,
reduces FAK phosphorylation [18]. Pathogen-associated
molecular patterns (PAMPs) induce interleukin 6 produc-
tion in rheumatoid synovial fibroblasts, which requires
FAK phosphorylation at tyrosine 397 [19,20]. Apart from a
role in synovial fibroblast invasion, FAK has been hy-
pothesized to be important in inflammatory arthritis
related to synovial angiogenesis [21] and could also
contribute through its role in regulating macrophage
invasion [22], neutrophil survival [23], T-cell activation
[24] and osteoclast function [25]. PF-573,228, another
FAK inhibitor, reduces macrophage recruitment and has
antiangiogenic properties [26], and both PF-562,271 and
PF-573,228 reduce injury-mediated fibrosis [27,28]. Thus,
there are many reasons to suspect that FAK might be im-
portant in rheumatoid arthritis and that FAK inhibitors
might be beneficial, but little has been done to test the role
of FAK in inflammatory arthritis.
In this study, we show that FAK inhibitors reduce
rheumatoid synovial fibroblast invasion and migration, but
that FAK itself is required only for synovial fibroblast inva-
sion, not migration or murine TNFα-induced arthritis.
Methods
Patients
Deidentified synovial fluid samples obtained during the
routine care of patients given a diagnosis of rheumatoid
arthritis by a rheumatologist were provided by physi-
cians not associated with this research. This researchdoes not meet the definition of human subjects research
as confirmed by the University of Wisconsin Institutional
Review Board.
Animals
Mice which overexpress one copy of the TNFα transgene
(line 3647) [29] on a C57BL/6 background (from Dr.
George Kollias and the Alexander Fleming Biomedical
Sciences Research Center, Varkiza, Greece) were crossed
with FAKf/f mice on a 129 background [30] and Rosa26-
CreERT2 mice [31] on a C57BL/6 background to ultim-
ately generate TNF+CreER+FAKf/f and TNF+CreER−FAKf/f
mice for experiments. Mice were cared for and killed in a
manner approved by the University of Wisconsin Animal
Care and Use Committee.
Synovial fibroblast cultures
Synovial fibroblast cultures were prepared from mouse
ankle joints and from human synovial fluid as previously
described [32,33]. Briefly, murine ankles were minced,
incubated with collagenase type IV (Worthington Bio-
chemical, Lakewood, NJ, USA) at 37°C, and large debris
was filtered out with a cell strainer. Cells were plated in a
culture medium composed of Dulbecco’s modified Eagle’s
medium with 10% fetal bovine serum (FBS), L-glutamine,
nonessential amino acids, essential amino acids, penicillin,
streptomycin and β-mercaptoethanol. Human synovial
fluid was centrifuged, and the cell pellet was resuspended
in the above media. Synovial fibroblasts were used be-
tween passages 5 and 9 unless otherwise stated. Before
use, mouse synovial fibroblasts were confirmed to express
vascular cell adhesion molecule 1 and not F4/80 or CD45,
and human synovial fibroblasts were confirmed to express
CD90 and not CD68 (data not shown). Cells were serum-
starved overnight before all invasion, migration and matrix
degradation experiments were carried out in media identi-
cal to that described above, but with only 0.1% FBS.Inhibition and depletion of focal adhesion kinase in vitro
Human rheumatoid synovial fibroblasts were treated with
5 μM PF-562,271 (Symansis, Timaru, New Zealand), 5 μM
PF-573,228 (Tocris Bioscience, Bristol, UK) or an equal
volume of dimethyl sulfoxide (DMSO) for 10 minutes at
room temperature before and also during migration, inva-
sion or degradation assays. The final concentration of
DMSO was 0.5% or less for all experiments. Dosing of
drugs and DMSO was based on previous studies [24]
and confirmed not to alter cell metabolism, viability and
function (data not shown). TNF+CreER+FAKf/f murine
synovial fibroblasts were treated with 1 μM (Z)-4-OH
tamoxifen (Sigma-Aldrich, St Louis, MO, USA) in 95%
ethanol or vehicle control (95% ethanol) for 4 days be-
fore experiments.
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Synovial fibroblasts were scraped into lysis buffer (5 mM
Tris, pH 7.4; 500 mM NaCl; 0.1% sodium monododecyl
sulfate; 0.5% deoxycholic acid; 0.5 mM MgCl2) contain-
ing 2 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pep-
statin, 0.2 mM phenylmethylsulfonyl fluoride and 1 mM
sodium vanadate on ice. Spleens were dissociated, and
splenocytes were lysed in lysis buffer after red blood cell
lysis. Equivalent amounts of cell lysates were subjected
to SDS-PAGE and transferred onto nitrocellulose mem-
branes for Western blotting using standard methods.
Blots were incubated with dilutions of 1:500 anti-FAK
(clone 77; BD Transduction Laboratories, San Jose, CA,
USA), 1:100 anti-phospho-Tyr-397 FAK (polyclonal anti-
body; Invitrogen, Carlsbad, CA, USA), 1:1,000 rabbit
anti-tubulin (Cell Signaling Technology, Danvers, MA,
USA) and/or 1:1,000 mouse anti-β-actin (clone AC-15;
Sigma-Aldrich). Secondary antibodies were used at 1:10,000
and were conjugated to IREDye 680 or 800 (LI-COR Bio-
sciences, Lincoln, NE, USA). Blots were imaged and bands
were quantified by densitometry using the Odyssey infrared
imaging system (LI-COR Biosciences).Invasion assay
Murine arthritic (2.5 ×104) or human rheumatoid (1.5 ×
104) synovial fibroblasts were pipetted into the upper wells
of Matrigel BioCoat Invasion Chambers (BD Biosciences,
San Jose, CA, USA) in 0.1% FBS media. The lower cham-
bers contained 10% FBS media as an attractant. Cells were
incubated for 24 hours at 37°C with 10% CO2. Noninvaded
cells were removed with a cotton swab, and the membranes
were fixed in methanol and stained with Hema 3 Manual
Staining System (Fisher Scientific, Asheville, NC, USA) ac-
cording to the manufacturer’s instructions. For each trans-
well membrane, the number of cells that invaded across the
membrane for ten microscopic fields at 100× magnification
were counted for human studies and four microscopic
fields at 100× magnification for mouse studies.Migration assay
Rheumatoid (3 × 104) and murine arthritic (2 × 104)
synovial fibroblasts in 0.1% FBS media were placed in
the upper chamber of a transwell previously coated with
10 μg/ml fibronectin and blocked with 2% bovine serum
albumin in phosphate-buffered saline (PBS). The lower
chamber contained 10% FBS media as an attractant.
After incubation for 4 hours (murine synovial fibro-
blasts) or 5 hours (human rheumatoid synovial fibro-
blasts) at 37°C with 10% CO2, nonmigrated cells were
removed with a cotton swab and the membranes were
fixed, stained and counted in the same manner as was
done for invasion assays.Gelatin degradation assay
Gelatin coverslips were prepared as published previously
[33]. Briefly coverslips were with treated with 50 μg/ml
poly-L-lysine, then 0.5% glutaraldehyde, then 0.2% Oregon
green gelatin (Molecular Probes, Eugene, OR, USA), then
5 mg/ml NaBH4, with PBS washes done between each
treatment. Rheumatoid synovial fibroblasts (7.5 × 103)
were plated on the coverslips in media with 10% FBS; in-
cubated for 2, 5 or 24 hours; fixed with 3% formaldehyde;
quenched with 0.15 M glycine; permeabilized with 0.2%
Triton-X 100; blocked with 5% goat serum; and incubated
with mouse anti-cortactin (1:200, clone 4F11; EMD Milli-
pore, Billerica, MA, USA), mouse anti-vinculin (1:500,
clone V284; EMD Millipore) and rabbit anti-paxillin
pY118 (1:200, polyclonal; BioSource International,
Camarillo, CA, USA), followed by washing and incubating
with either goat anti-mouse rhodamine red or donkey
anti-rabbit tetramethylrhodamine (1:250). Coverslips were
mounted and viewed at 400× magnification with an
inverted fluorescence microscope (Nikon Eclipse TE300;
Nikon Instruments, Melville, NY, USA). Images were digit-
ally acquired and processed with MetaMorph software
(Molecular Devices, Sunnyvale, CA, USA) and ImageJ soft-
ware (National Institutes of Health, Bethesda, MD, USA).
Focal adhesion kinase depletion in vivo
To delete fak, mice were injected intraperitoneally at 6
weeks of age (when arthritis is typically not clinically ap-
parent) with 1 mg of tamoxifen in 1 ml of sunflower oil a
total of three times with each dose 3 days apart. All experi-
ments were performed using TNF+CreER+FAKf/f mice
treated with tamoxifen and littermate controls that were
either TNF+CreER+FAKf/f mice treated with sunflower oil
or TNF+CreER−FAKf/f mice treated with tamoxifen. No
difference was seen using these two different controls, and
data were pooled.
Clinical arthritis scores
Arthritis was scored by the same investigator in a blinded
manner on a scale of 0 to 3 as described previously [34],
with 0 = no arthritis; 0.5 = mild joint deformity, mild
swelling; 1.0 = moderate joint deformity, moderate swell-
ing; 1.5 = moderate/severe joint deformity, moderate
swelling, decreased grip strength on a metal wire; 2.0 = se-
vere joint deformity, moderate swelling, no grip strength;
2.5 = severe joint deformity, moderate/severe swelling, no
grip strength, and 3.0 = severe joint deformity and swell-
ing, no grip strength.
Pathology
Hind legs were fixed in neutral buffered 10% formalin
and decalcified with Surgipath Decalcifier I (Leica Bio-
systems, Buffalo Grove, IL, USA) for 30 hours. Tissue
was embedded, sectioned and stained with hematoxylin
Figure 1 Focal adhesion kinase inhibitors reduce synovial
fibroblast invasion in vitro. Human rheumatoid synovial fibroblasts
were treated with focal adhesion kinase (FAK) inhibitors for 30
minutes or 5 hours. Cells were lysed and subjected to Western blot
analysis for total FAK and FAK phosphorylated at tyrosine 397
(pY397). Bands were quantified by densitometry. Representative blot
is shown in (A). (B) Graph depicts phosphorylated FAK divided by
total FAK (n = 3 independent experiments using cell lines from two
different patients). (C) Rheumatoid synovial fibroblasts were treated
with PF-562,271, PF-573,228 or dimethyl sulfoxide (DMSO) as the
vehicle control and allowed to invade for 24 hours in Matrigel invasion
chambers. Graph shows the number of invaded cells per microscopic
field at 100× magnification (n = 4 replicates using cell lines from three
different patients). All graphs show average ± standard error of the
mean (SEM) data with *P < 0.05 and ****P < 0.0001 by one-way
analysis of variance.
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joint was scored by a single pathologist who was blinded
to the genotype of the mice. The pathology scoring scale
for synovitis is as follows: 0 = none, 1 = mild, 2 = mod-
erate, 3 = moderately severe and 4 = severe. The sever-
ity scale for erosion is as follows: 0 = none, 1 = erosion
of one surface of the tibiotalar joint with less than 50%
involvement, 2 = erosion of less than 50% of both sur-
faces of the tibiotalar joint, 3 = erosion of more than
50% of both surfaces of the tibiotalar joint and 4 =
complete destruction of the tibiotalar joint.
Statistics
Significance was determined using one-way analysis of
variance with post hoc tests or paired and unpaired t-
tests as appropriate (GraphPad Prism software; Graph-
Pad Software, La Jolla, CA, USA).
Results
To assess whether FAK activation is important for syn-
ovial fibroblast invasion, we first confirmed inhibition of
FAK in rheumatoid synovial fibroblasts. Synovial fibro-
blasts derived from the synovial fluid of patients with
rheumatoid arthritis were treated for either 30 minutes
or 5 hours with vehicle control or either of the FAK in-
hibitors PF-562,271 or PF-573,228. Cell lysates were sub-
jected to Western blot analysis to assess levels of FAK
phosphorylated at tyrosine 397. As shown in Figures 1A
and 1B, at both 30 minutes and 5 hours, there was a sig-
nificant reduction in pY397 FAK with FAK inhibition
compared to vehicle control. Next, synovial fibroblasts
were treated with DMSO, PF-562,271 or PF-573,228 and
allowed to invade for 24 hours through Matrigel invasion
chambers. As shown in Figure 1C, there was a threefold
reduction in the ability of FAK-inhibited synovial fibro-
blasts to invade. Thus, activated FAK appears to be im-
portant for the invasive capability of human rheumatoid
synovial fibroblasts through a three-dimensional matrix
in vitro.
Two major components of cellular invasion are deg-
radation of extracellular matrix and migration. Given the
deficits seen in invasion after FAK inhibition, we sought
to determine whether these components of invasion
would be affected by FAK inhibitors. We first addressed
matrix degradation and started by characterizing the pat-
tern of degradation in rheumatoid synovial fibroblasts.
We plated rheumatoid synovial fibroblasts on fluorescent
gelatin-coated coverslips and allowed them to degrade for
2 hours. We then fixed the cells and stained them for cor-
tactin, a cytoskeletal protein found in invadopodia [35]. As
shown in Figure 2A, gelatin degradation was seen in the
central portion of many cells colocalizing with cortactin
staining, consistent with the invadopodia previously re-
ported in synovial fibroblasts [5]. However, we also sawdegradation that did not colocalize with cortactin at the
cell periphery, where focal adhesions are located. Similar
patterns were seen at the 5- and 24-hour time points (data
not shown). To determine whether the peripherally de-
grading structures were focal adhesions, we repeated the
degradation experiments and stained for vinculin and pax-
illin, two cytoskeletal proteins typically seen in focal adhe-
sions [36]. As shown in Figures 2B and 2C, staining for
vinculin and paxillin aligned with the peripheral degrad-
ation areas, suggesting that rheumatoid synovial fibro-
blasts may use both invadopodia and focal adhesions to
degrade matrix, similarly to cancer cells [8].
Having characterized the degradative structures of these
rheumatoid arthritis synovial fluid–derived synovial fibro-
blasts, we next sought to determine whether FAK inhibitors
Figure 2 Rheumatoid synovial fibroblasts degrade centrally and at focal adhesions. Rheumatoid synovial fibroblasts were allowed to
adhere for 2 hours to coverslips coated with fluorescently labeled gelatin. Coverslips were fixed and stained for cortactin, vinculin and paxillin.
Images are representative of gelatin degradation and staining for cortactin (A), vinculin (B) and paxillin (C) in three independent experiments in which
we used rheumatoid synovial fibroblasts from two different patients. Images were made at 400× magnification, and the bar represents 50 μm. To
demonstrate degradation at focal adhesions, boxes indicate examples of areas where gelatin degradation did not colocalize with cortactin (A), a
marker of invadopodia, as well as where gelatin degradation did colocalize with vinculin (B) and paxillin (C), two markers of focal adhesions.
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fibroblasts were treated with FAK inhibitors or vehicle con-
trol and allowed to degrade fluorescent gelatin for 5 hours.
Coverslips were stained for vinculin to localize the struc-
tures of the cells. As shown in Figure 3A, FAK-inhibited
cells appear to have normal matrix degradation. We then
scored the cells for degradation as outlined in Figure 3B.
Central degradation appeared to either be present or ab-
sent, so synovial fibroblasts were scored with either a 0 or a
1 for the absence or presence of degradation, respectively.
As shown in Figure 3C, there was no difference in central
degradation scores upon FAK inhibition. There was more
variation in the extent of degradation at the periphery, so
this was scored as 0 (none), 1 (mild) or 2 (severe) for each
cell. There was no difference in degradation at focal adhe-
sions with FAK inhibition (Figure 3D). Similar results were
seen after 24 hours of incubation of synovial fibroblasts on
gelatin (data not shown).
We then sought to determine whether FAK inhibition
could alter rheumatoid synovial fibroblast migration.
Rheumatoid synovial fibroblasts were treated with FAK in-
hibitors or vehicle control and allowed to migrate across
fibronectin-coated transwells for 5 hours. As shown in
Figure 3E, migration was impaired when FAK was inhib-
ited. Taken together, these data suggest that FAK inhibitors
impair the migratory component of synovial fibroblast inva-
sion, but not focal matrix degradation.
Because FAK inhibitors reduced rheumatoid synovial
fibroblast invasion and migration, which are two importantcomponents of rheumatoid arthritis progression, we evalu-
ated whether FAK protein itself contributes to synovial
fibroblast invasion and arthritis severity. To do so, we gen-
erated a mouse model of arthritis in which fak could be de-
leted upon exposure to tamoxifen. We crossed TNFα-
overexpressing mice, which develop a chronic inflamma-
tory, erosive arthritis similar to rheumatoid arthritis [29],
with FAKf/f mice, in which the fak gene is floxed [30], and
Rosa26-CreERT2 mice [31], in which Cre recombinase de-
letes floxed genes upon exposure to tamoxifen. We ultim-
ately generated TNF+CreER+FAKf/f and TNF+CreER−FAKf/f
mice for experiments.
Before addressing arthritis, we evaluated whether FAK
protein is important for murine arthritic synovial fibroblast
invasion. We generated synovial fibroblasts from TNF
+CreER+FAKf/f and TNFα-overexpressing mice that lacked
Cre recombinase. TNF+CreER+FAKf/f synovial fibroblast
cultures were treated in vitro with (Z)-4-OH tamoxifen or
vehicle control for 4 days and cell lysates were analyzed by
western blot to quantify the loss of FAK. As shown in
Figure 4A and B, there was a dramatic reduction in
FAK protein in the TNF+CreER+FAKf/f synovial fibro-
blasts treated with (Z)-4-OH tamoxifen. We then
treated TNF+CreER+FAKf/f and TNFα-overexpressing
synovial fibroblasts without Cre with either (Z)-4-OH
tamoxifen or vehicle control for 4 days, followed by
subjecting the synovial fibroblasts to the Matrigel inva-
sion chamber assay as described above. As shown in
Figure 4C, invasion was impaired only in the TNF
Figure 3 Focal adhesion kinase inhibitors do not alter focal matrix degradation, but do reduce migration of rheumatoid synovial
fibroblasts. (A) Rheumatoid synovial fibroblasts were treated with PF-562,271, PF-573,228 or dimethyl sulfoxide (DMSO) as the vehicle control,
plated on fluorescently labeled gelatin, fixed after 5 hours and stained for vinculin. Representative images of matrix-degrading cells from each condition
are displayed (n = 3 independent experiments using cell lines from two different patients). Images were created at 400× magnification, and the bar
represents 50 μm. (B) Left panel depicts a scoring system for gelatin degradation: 1 = no peripheral degradation (note: for quantitative analyses in
(C) and (D), only cells that were completely within the field of view were scored), 2 = central and severe peripheral degradation, 3 = severe peripheral
degradation and no central degradation and 4 = mild peripheral degradation and no central degradation. Cells treated as in (A) were scored for
degradation as described in for (B). (C) and (D) Graphs show the average scores ± SEM for central (C) and peripheral (D) degradation (n = 3
independent experiments using cell lines from two different patients). (E) Rheumatoid synovial fibroblasts were treated with PF-562,271,
PF-573,228 or vehicle control (DMSO) and allowed to migrate for 5 hours across a transwell. The graph shows average number ± SEM of
migrated cells per microscopic field at 100× magnification (n = 4 independent experiments using cell lines from three different patients,
*P < 0.05 by one-way analysis of variance).
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OH tamoxifen, suggesting that FAK is necessary for
efficient murine synovial fibroblast invasion into three-
dimensional matrix in vitro.
We also tested whether FAK protein would be required
for murine arthritic synovial fibroblast migration. TNF
+CreER+FAKf/f and TNFα-overexpressing synovial fibro-
blasts without Cre were treated with either (Z)-4-OH tam-
oxifen or vehicle control as described above and then
allowed to migrate across fibronectin-coated transwells for
4 hours. Interestingly, in contrast to the reduction inmigration in the presence of FAK inhibitors, there was no
defect in murine synovial fibroblast migration after dele-
tion of fak (Figure 4D). To be sure that this discrepancy
was not related to the difference in species, type of arth-
ritis or source of synovial fibroblasts (synovial fluid versus
synovial tissue), we treated murine arthritic synovial fi-
broblasts with DMSO, PF-562,271 or PF-573,228 (as de-
scribed above) and then allowed them to migrate across
fibronectin-coated transwells for 4 hours. As shown in
Figure 4E, synovial fibroblast migration was reduced with
the FAK inhibitors. Taken together, these data suggest that
Figure 4 Focal adhesion kinase depletion reduces murine arthritic synovial fibroblast invasion, but not migration, in vitro. TNF+CreER
+FAKf/f murine synovial fibroblasts were treated with either (Z)-4-OH tamoxifen (OHT) or 95% ethanol vehicle control (EtOH). Cell lysates were
subjected to Western blot analysis for focal adhesion kinase (FAK) and actin to test for FAK depletion. (A) A representative blot from seven
experiments is presented. (B) Densitometry was performed, and the average ± SEM for data for the amount of FAK divided by actin are shown
(n = 7, ****P < 0.0001 by t-test). (C) TNF+CreER+FAKf/f (+CreER) and TNF+CreER−FAKf/f or TNF+CreER−FAK+/+ (−CreER) murine synovial fibroblasts
were treated with OHT or EtOH for 4 days and then allowed to invade for 24 hours through Matrigel invasion chambers. The number of invaded
cells per microscopic field at 100× magnification was counted, and OHT-treated samples were normalized to EtOH-treated controls. Graph depicts
average ± SEM (n = 3, **P < 0.01, ***P < 0.005 by one-way analysis of variance (ANOVA)). (D) +CreER and –CreER murine synovial fibroblasts were
treated as in (C) and allowed to migrate across fibronectin-coated transwells for 4 hours. The number of migrated cells per microscopic field at
100× magnification was counted, and OHT-treated samples were normalized to EtOH-treated controls. Graph depicts average ± SEM data (n = 3).
(E) Murine TNFα-overexpressing synovial fibroblasts were treated with dimethyl sulfoxide (DMSO) vehicle control, PF-562,271 or PF-573,228 and
allowed to migrate across fibronectin-coated transwells for 4 hours. The number of invaded cells per microscopic field at 100× magnification was
counted. Graph depicts average ± SEM data (n = 4, *P < 0.05 by one-way ANOVA).
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and migration, FAK itself is required for synovial fibroblast
invasion into three-dimensional matrix, but is not required
for two-dimensional migration on fibronectin.
Because murine arthritic synovial fibroblasts had im-
paired invasion upon FAK depletion, we sought to de-
termine if TNFα-induced arthritis would be lessened in
the absence of FAK. TNF+CreER+FAKf/f mice were
treated with tamoxifen at 6 weeks of age. For controls,
TNF+CreER+FAKf/f littermates were treated with ve-
hicle alone and TNF+CreER−FAKf/f littermates were
treated with tamoxifen. To confirm depletion of FAK,
spleens were harvested and subjected to Western blot
analysis. As shown in Figures 5A and 5B, there was a
significant reduction in FAK levels upon tamoxifen
treatment. We attempted to detect depletion of FAK inthe joint, but FAK levels in arthritic mice not treated
with tamoxifen were below the level of detection of our
Western blots. Therefore, we generated a line of synovial
fibroblasts from a 5-month-old CreER+FAKf/f mouse
treated with tamoxifen as described above. At passage 3,
lysates were made and subjected to Western blot analysis.
As shown in Figure 5C, these synovial fibroblasts also
showed substantial depletion of FAK protein compared to
FAK levels in normal synovial fibroblasts. Similar results
were seen at earlier time points after tamoxifen treatment
(data not shown).
Having confirmed FAK depletion, we clinically scored
arthritis monthly until the mice were 5 months of age.
The scoring was done in a blinded manner at the hind feet
based on joint deformity, swelling and grip strength. As
shown in Figure 5D, there was no significant difference in
Figure 5 Focal adhesion kinase depletion does not reduce synovial fibroblast invasion into cartilage and bone or clinical arthritis in
murine tumor necrosis factor α–induced arthritis. TNF+CreER+FAKf/f mice were treated with tamoxifen at 6 weeks of age (FAK−/−). For each
experimental mouse, there was a littermate control (FAKf/f) that was either a TNF+CreER+FAKf/f mouse treated with vehicle or a TNF+CreER−FAKf/f
mouse treated with tamoxifen. Spleen lysates from FAKf/f and FAK−/− mice at 5 months of age were subjected to Western blot analysis to detect
focal adhesion kinase (FAK) and tubulin. A representative blot is presented in (A). (B) Densitometry was performed, and the average ± SEM data
for FAK levels normalized to tubulin are presented in the graph (n = 3, *P < 0.05 by t-test). (C) Synovial fibroblasts derived from the tibiotalar
joints of a 5-month-old FAK−/− mouse and a FAK+/+ mouse were expanded to passage 3. Lysates from these synovial fibroblasts were subjected
to Western blot analysis for FAK and tubulin. (D) Arthritis was clinically scored in FAK−/− and littermate control FAKf/f mice based on hind foot
deformity, swelling and grip strength on a scale of 0 to 3. Average ± SEM data are presented in the graph (n = 12 sex-matched pairs at 2, 3 and
4 months and n = 8 pairs at 5 months). The tibiotalar joint was fixed, decalcified, embedded and sectioned for hematoxylin and eosin staining
when the mice were 5 months of age. Representative images are shown in (E). Inset shows areas of pannus invading cartilage (arrows) and bone
(arrowheads). Bar represents 200 μm. (F) Joints were scored for severity of synovitis, cartilage erosion and bone erosion on a scale of 0 to 4, with
average ± SEM data presented in the graph (n = 6 pairs).
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were 5 months of age, their hind legs were fixed, decalci-
fied, sectioned and stained with H&E (Figure 5E). The
tibiotalar joints were scored in a blinded manner based on
synovitis and joint erosion. As shown in Figure 5F, there
was no difference in either synovitis or erosive disease in
the absence of FAK. Thus, although FAK is required
in vitro for synovial fibroblast invasion, it is dispensable
for inflammatory arthritis and joint erosions.Discussion
In this study, we have demonstrated that FAK is re-
quired for arthritic synovial fibroblast invasion in vitro
(Figures 1 and 4). FAK has already been shown to be im-
portant for cytokine production in synovial fibroblasts
[19,20], but, to our knowledge, this study is the first to
show FAK’s role in invasion in these cells. However, despite
the significant reduction in synovial fibroblast invasion
in vitro when FAK is inhibited or depleted and in spite of
the known role for synovial fibroblasts in erosive disease
[2,3], joint erosions in TNFα-induced inflammatory arth-
ritis were unaltered after deletion of FAK (Figure 5), sug-
gesting different molecular requirements for cellular
invasion in vitro versus in vivo.There are several possible reasons why inflammatory ero-
sive arthritis is not altered in FAK-deficient mice. First, al-
though we observed that depletion of FAK was quite good,
there may still have been some residual FAK allowing dis-
ease progression. Second, it is possible that this model of
arthritis is not FAK-dependent. Third, in vitro invasion was
reduced, not eliminated, in the absence of FAK, and the re-
sidual amount of invasion may have been sufficient for
arthritis and joint erosions. Fourth, we found that activated
FAK was not required for focal matrix degradation in
rheumatoid synovial fibroblasts (Figure 3). Similar phenom-
ena were seen in macrophages in which FAK was required
for invasion, but not focal matrix degradation by podo-
somes [22]. In breast cancer cells, FAK is required for inva-
sion, but is a negative regulator of invadopodia formation
[37]. When FAK is depleted in human fibrosarcoma cells,
more than half of cells can still degrade at focal adhesions
[8]. Thus, perhaps, joint invasion depends primarily on
matrix degradation, which is FAK-independent. In locations
where the synovium contacts the joint, invasion occurs
slowly over weeks and months. Perhaps bone and cartilage
can be destroyed simply by local, constant degradation.
A final possible reason why murine inflammatory arth-
ritis may not be reduced upon depletion of FAK may be
that Pyk2 (proline-rich tyrosine kinase), a homologue of
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http://arthritis-research.com/content/16/5/464FAK, can compensate for loss of FAK. Rheumatoid syn-
ovial tissue has elevated phosphorylated Pyk2, and TNFα
can induce Pyk2 phosphorylation in rheumatoid synovial
fibroblasts [17]. Further, like FAK, Pyk2 is important for
T-cell, neutrophil and macrophage functions [38-40]. In a
previous study, when FAK-related nonkinase (FRNK), an
endogenous FAK inhibitor, was overexpressed intraarticu-
larly in a model of rat arthritis, bone erosions and osteo-
clasts were reduced [25]. However, FRNK has been shown
to inhibit both FAK and Pyk2 [41], and FAK and Pyk2
function synergistically in osteoclast podosome formation
[42]. Therefore, FAK and Pyk2 may have overlapping roles
in inflammatory arthritis. We have looked at Pyk2 levels
in synovial fibroblasts in which FAK has been deleted and
have seen no changes in Pyk2 levels (data not shown).
However, even without a change in Pyk2 levels, the nor-
mal amount of Pyk2 might be sufficient to compensate for
loss of FAK in inflammatory arthritis.
We also found that FAK inhibitors reduced synovial fibro-
blast migration, but that FAK protein itself did not appear to
be required. This is surprising because FAK is required for
migration in other cell types, such as macrophages, although
in the macrophage experiments described in [22], transwells
were not coated with fibronectin, which might lead to an al-
tered need for FAK. It is possible that residual amounts of
FAK after deletion were sufficient to allow migration. How-
ever, FAK depletion appeared more robust (Figure 4) than
FAK inhibition (Figure 1). Another possibility is that cells
may compensate for the loss of FAK better than inhibition of
FAK, because, in the case of inhibition, the FAK molecule is
still present and cannot necessarily be replaced by a similar
protein. One final explanation for the discrepancy between
the FAK inhibitors and FAK depletion is that FAK inhibi-
tors also inhibit Pyk2 and several cyclin-dependent kinases
[43]. Perhaps inhibition of at least one of these other mole-
cules is necessary in addition to inhibition of FAK itself to
reduce synovial fibroblast migration in transwell experi-
ments. Such off-target effects of the FAK inhibitors may
contribute to their efficacy in cancer and may also make
them efficacious in rheumatoid arthritis, despite the fact
that depletion of FAK alone appears to have no effect in
synovial fibroblast migration or arthritis.
We have further characterized the structures used by
rheumatoid synovial fibroblasts to invade. Others have re-
ported that arthritic synovial fibroblasts make invadopodia
[5,6]. We did see central areas of degradation colocalizing
with cortactin, but we also saw degradation at focal adhe-
sions. Because degradation at focal adhesions has not been
reported previously in human synovial fibroblasts, it is pos-
sible that this is a unique feature of synovial fibroblasts iso-
lated from synovial fluid. However, this is unlikely because
peripheral degradation also occurs in murine arthritic syn-
ovial fibroblasts generated from synovial tissue [33]. To the
best of our knowledge, we are the first to observe focaladhesion degradation in nonmalignant human cells, which
is interesting, given the comparisons made between the
rheumatoid pannus and tumors [1]. Therefore, degradation
at focal adhesions may be a special pathologic feature of
rheumatoid synovial fibroblasts.
Conclusions
We show that FAK contributes to synovial fibroblast inva-
sion, but is dispensable in TNFα-driven erosive arthritis.
Further, we found that rheumatoid synovial fibroblasts ap-
pear to degrade at both invadopodia and focal adhesions,
which may contribute to the pathophysiology of rheuma-
toid arthritis. Further studies are needed to address the
role of Pyk2 and other mediators of cellular invasion and
migration in inflammatory arthritis.
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